BioNTech reports Q1 2026 loss amid lower COVID-19 vaccine sales, advances oncology pipeline with new trials and cost cuts.

In Q1 2026, BioNTech posted revenues of €118.1 million, down from €182.8 million due to reduced COVID-19 vaccine sales, and a net loss of €531.9 million. The company is focusing on expanding its oncology pipeline with five new pivotal trials for pumitamig and other immuno-oncology programs, expecting six late-stage data readouts this year. BioNTech plans to consolidate manufacturing sites to save up to €500 million annually by 2029 and has initiated a $1 billion share repurchase program. It reaffirmed its 2026 revenue guidance of €2.0-2.3 billion, aiming to become a leading multi-product biopharma company by 2030.